Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00092924 · ClinicalTrials.gov registry record · Phase 2
Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Human Genome Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00092924 is a Phase 2 study that has completed, run by Human Genome Sciences.
The verdict
NCT00092924, a Phase 2 study, has completed, sponsored by Human Genome Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
Interventions
- DRUG TRAIL-R1 mAb (TRM-1;HGS-ETR1)
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00092924
The ClinicalTrials.gov registry entry for NCT00092924 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Human Genome Sciences, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TRAIL-R1 mAb (TRM-1;HGS-ETR1) is the first listed.
NCT00092924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00092924 about?
NCT00092924 is a clinical study titled "Study of TRM-1(TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)". The purpose of this study is to evaluate the efficacy and safety of TRM-1 in subjects with relapsed or refractory non-small cell lung cancer.
What is the current status of trial NCT00092924?
This trial is currently completed. It is a Phase 2 study. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00092924?
The interventions under investigation include: TRAIL-R1 mAb (TRM-1;HGS-ETR1) (DRUG).
Who is sponsoring clinical trial NCT00092924?
This trial is sponsored by Human Genome Sciences, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.